Immunohistochemical analysis of nuclear survivin expression in esophageal squamous cell carcinoma

被引:38
作者
Mega, S.
Miyamoto, M.
Li, L.
Kadoya, M.
Takahashi, R.
Hase, R.
Kaneko, H.
Shichinohe, T.
Kawarada, Y.
Itoh, T.
Morikawa, T.
Kondo, S.
机构
[1] Hokkaido Univ, Grad Sch Med, Dept Surg Oncol, Div Canc Med, Sapporo, Hokkaido, Japan
[2] Hokkaido Univ Hosp, Dept Pathol, Sapporo, Hokkaido 060, Japan
关键词
carcinogenesis; esophageal squamous cell carcinoma; immunohistochemistry; prognosis; survivin;
D O I
10.1111/j.1442-2050.2006.00604.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Despite advances in the treatment of esophageal carcinoma, the prognosis for this disease remains poor. Therefore, it is important to obtain a better understanding of the molecular basis of esophageal carcinogenesis. The purpose of this study was to clarify the roles of survivin in esophageal squamous cell carcinoma (ESCC). One hundred 22 ESCC surgical specimens resected from 1989 to 1999 were examined. Survivin expression was assessed by immunohistochemistry. Tumor cells were considered survivin-positive if the immunoreactivity was confined to the nucleus, and a scoring method was applied. Survivin-positive immunostaining was detected in 68 patients (56%). There was a significant association between survivin expression and pN (P = 0.0472). Moreover, the overall survival rate was worse in patients with survivin-positive tumors than in patients with survivin-negative tumors (P = 0.0189). The overexpression of survivin was associated with the overall survival rate and poor prognosis in patients with ESCC. Survivin may be targeted during cancer therapy because of its selective expression in malignant tissue.
引用
收藏
页码:355 / 359
页数:5
相关论文
共 24 条
[1]   Validating survivin as a cancer therapeutic target [J].
Altieri, DC .
NATURE REVIEWS CANCER, 2003, 3 (01) :46-54
[2]   The molecular basis and potential role of survivin in cancer diagnosis and therapy [J].
Altieri, DC .
TRENDS IN MOLECULAR MEDICINE, 2001, 7 (12) :542-547
[3]   Survivin and apoptosis control [J].
Altieri, DC .
ADVANCES IN CANCER RESEARCH, VOL 88, 2003, 88 :31-52
[4]  
Altieri DC, 1999, LAB INVEST, V79, P1327
[5]   A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].
Ambrosini, G ;
Adida, C ;
Altieri, DC .
NATURE MEDICINE, 1997, 3 (08) :917-921
[6]   Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years [J].
Ando, N ;
Ozawa, S ;
Kitagawa, Y ;
Shinozawa, Y ;
Kitajima, M .
ANNALS OF SURGERY, 2000, 232 (02) :225-232
[7]   A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group Study [J].
Ando, N ;
Iizuka, T ;
Kakegawa, T ;
Isono, K ;
Watanabe, H ;
Ide, H ;
Tanaka, O ;
Shinoda, M ;
Takiyama, W ;
Arimori, M ;
Ishida, K ;
Tsugane, S .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1997, 114 (02) :205-209
[8]   Cytokine-regulated expression of survivin in myeloid leukemia [J].
Carter, BZ ;
Milella, M ;
Altieri, DC ;
Andreeff, M .
BLOOD, 2001, 97 (09) :2784-2790
[9]   Skeletonizing en bloc esophagectomy for cancer [J].
Collard, JM ;
Otte, JB ;
Fiasse, R ;
Laterre, PF ;
De Kock, M ;
Longueville, J ;
Glineur, D ;
Romagnoli, R ;
Reynaert, M ;
Kestens, PJ .
ANNALS OF SURGERY, 2001, 234 (01) :25-32
[10]   Hodgkin and Reed-Stemberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints:: analyses using tissue microarrays [J].
García, JF ;
Camacho, FI ;
Morente, M ;
Fraga, M ;
Montalbán, C ;
Alvaro, T ;
Bellas, C ;
Castaño, A ;
Díez, A ;
Flores, T ;
Martín, C ;
Martínez, MA ;
Mazorra, F ;
Menárguez, J ;
Mestre, MJ ;
Mollejo, M ;
Sáez, AI ;
Sánchez, L ;
Piris, MA .
BLOOD, 2003, 101 (02) :681-689